TICKERNERD
Menu
KVUEKVUEConsumer Defensive · Household & Personal Products

KVUE Stock Forecast: Kenvue, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$20
−1.56% on the day

The 14 Wall Street analysts covering Kenvue, Inc. hold a median 12-month price target of $19 — -2.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 22 Oct 2026 — in the upper half. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$38.2B
Ticker Nerd rank
70/ 100
Median analyst target
$19
Analysts covering
14
Revenue$4.0B+3.0% y/y
Operating income$758.0M
Net income$456.0M
Free cash flow$624.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.5%
1M
+10.8%
YTD
+18.8%
1Y
+37.5%
From 52W high
−1.6%
From 52W low
+45.7%
$13
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KVUE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kenvue, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
70/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
91
Value
82
Issuance
79
Momentum
71
Quality
63
Growth
56
Accruals
54
Revisions
53
Size
6

Volatility (91): The share price has been relatively steady.

Revisions (53): Analysts have, on balance, been cutting their forecasts.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KVUE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KVUE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$12$14$16$18$20$22$24Jan 26Apr 26Jul 26Oct 26KVUEHigh $23Median $19Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
2 Buy12 Hold0 Sell
Low $18Median $19High $23

The green dot is the last close — the median target sits −2.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
11 Aug 2026UBSMaintainsNeutral$20 → $19
21 July 2026BarclaysMaintainsEqual-Weight$18 → $19
21 July 2026BarclaysMaintainsEqual-Weight—
16 July 2026UBSMaintainsNeutral$18 → $20
16 July 2026UBSMaintainsNeutral—
15 Apr 2026CitigroupMaintainsNeutral$20 → $19
15 Apr 2026CitigroupMaintainsNeutral—
14 Apr 2026BarclaysMaintainsEqual-Weight$19 → $18
14 Apr 2026BarclaysMaintainsEqual-Weight—
7 Apr 2026UBSMaintainsNeutral—
6 Mar 2026BarclaysMaintainsEqual-Weight—
18 Feb 2026Canaccord GenuityMaintainsHold—
18 Feb 2026CitigroupMaintainsNeutral—
18 Feb 2026UBSMaintainsNeutral—
30 Jan 2026JefferiesDowngradeHold—
10 Nov 2025BarclaysMaintainsEqual-Weight—
29 Oct 2025Canaccord GenuityDowngradeHold—
27 Oct 2025JefferiesMaintainsBuy—
10 Oct 2025JP MorganMaintainsOverweight—
9 Oct 2025CitigroupMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

KVUE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

KVUE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, Kenvue, Inc. returned +37.5% against +14.3% for the S&P 500, dividends included.

KVUE vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26KVUES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KVUE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.7%
Analysts raising
1
Analysts cutting
1
Fundamentals

Kenvue, Inc. (KVUE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.1×

Cheaper than 33% of US stocks

Price / sales
2.5×

Cheaper than 46% of US stocks

Price / book
3.6×

Cheaper than 26% of US stocks

EV / EBITDA
13.1×

Cheaper than 27% of US stocks

Growth & margins
Revenue growth (YoY)
3.0%

Higher than 34% of US stocks

Earnings growth (YoY)
8.6%

Higher than 46% of US stocks

Gross margin
58.2%

Higher than 71% of US stocks

Operating margin
19.4%

Higher than 78% of US stocks

Net margin
10.8%

Higher than 71% of US stocks

Returns & dividend
Return on equity
15.6%

Higher than 75% of US stocks

Return on assets
7.0%

Higher than 85% of US stocks

Dividend yield
4.2%

Higher than 91% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kenvue, Inc. (KVUE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kenvue, Inc. has a market value of $38.2B and an enterprise value of $45.7B.

  • Revenue in the twelve months to 30 June 2026: $15.4B. The latest quarter grew 3.0% year on year.

  • Net income over the same four quarters: $1.7B, a 10.8% net margin.

  • Diluted earnings per share, trailing twelve months: $0.87.

  • Free cash flow in the twelve months to 30 June 2026: $1.9B.

  • Kenvue, Inc. spent $70.0M on share buybacks and $1.6B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 1.9B.

  • Trailing P/E: 23.1×; forward P/E: 16.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 4.22%, paying out 97% of earnings.

  • Kenvue, Inc. employs 21,780 people — $707K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 23 Oct 2026

Data provided by Twelve Data

Peers

KVUE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHousehold & Personal Products
CompanyMarket capTKN rank
KVUEKenvue, Inc.$38.2B70
ELThe Estée Lauder Companies, Inc.$37.6B91
KMBKimberly-Clark Corp.$37.3B65
CHDChurch & Dwight Co., Inc.$25.8B77
CLColgate-Palmolive Co.$78.5B91
CLXThe Clorox Co.$10.8B29
ELFe.l.f. Beauty, Inc.$6.9B45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kenvue, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KVUE news & analysis

3 Beauty Stocks to Explore as Consumer Preferences Reshape the Market

Zacks Investment Research · 22 Oct 2026neutral

Zacks Investment Research highlights clean beauty, innovation and digital shopping as forces reshaping the beauty industry, and discusses how ELF, EL and ULTA are responding to changing consumer preferences.

Why it matters — The item describes shifts in beauty-market preferences that may be relevant to monitoring Kenvue’s consumer-products landscape, but it does not discuss Kenvue directly.

Kenvue to Announce Third Quarter 2026 Results on October 30, 2026

Business Wire · 21 Oct 2026neutral

Kenvue said it will announce third-quarter 2026 financial results before the market opens on October 30, 2026. Because of its pending transaction with Kimberly-Clark, the company will not host a quarterly conference call to review the results.

Why it matters — KVUE watchers can note the scheduled results release and that no quarterly review call is planned.

October's 5 Dividend Growth Stocks With Yields Up To 7.99%

Seeking Alpha · 19 Oct 2026neutral

Seeking Alpha described its monthly screen for dividend-growth stocks with relatively higher yields, incorporating dividend consistency and safety grades. The article then reviews the five leading results for possible further research.

Why it matters — The excerpt does not say whether Kenvue was among the five stocks, so it offers no specific information about KVUE.

Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up

WSJ · 13 Oct 2026positive

Kimberly-Clark and Kenvue won conditional EU approval for their $40 billion tie-up. The European Commission said the sale fully addresses concerns about potential competition impacts in tampon markets in Czechia, Estonia, and Slovakia.

Why it matters — The approval update concerns Kenvue’s proposed tie-up and its resolution of the EU’s stated competition concerns.

Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers

PRNewsWire · 13 Oct 2026neutral

Kimberly-Clark said it received the required consents to adopt proposed amendments to the indenture governing all outstanding Kenvue notes. The announcement was based on early tenders in exchange offers involving up to $7 billion in new Kimberly-Clark notes and cash, alongside related consent solicitations.

Why it matters — The proposed amendments and exchange offers could change the terms governing Kenvue’s outstanding notes.

FAQ

Frequently asked questions about KVUE stock

What is the KVUE stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Kenvue, Inc. have a median 12-month price target of $19, with estimates ranging from $18 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KVUE stock a buy right now?

Of the 14 analysts covering Kenvue, Inc., 2 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kenvue, Inc. 70 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KVUE?

As at 22 Oct 2026, Kenvue, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (91 of 100).

Will KVUE stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies -2.9% from the last close, and Ticker Nerd's factor model ranks Kenvue, Inc. 70 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KVUE stock forecast for 2030?

No analyst covering Kenvue, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KVUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $23 over the next 12 months.

How has KVUE stock performed over the past year?

Kenvue, Inc. returned +37.5% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kenvue, Inc. do?

Kenvue Inc. is a consumer health company that develops, markets, and sells everyday health and personal care products for consumers around the world.

What is the latest news on KVUE?

The most recent item we track (Zacks Investment Research, 22 Oct 2026): "3 Beauty Stocks to Explore as Consumer Preferences Reshape the Market". Zacks Investment Research highlights clean beauty, innovation and digital shopping as forces reshaping the beauty industry, and discusses how ELF, EL and ULTA are responding to changing consumer preferences.

Company

About Kenvue, Inc.

Kenvue Inc. is a consumer health company that develops, markets, and sells everyday health and personal care products for consumers around the world. Its portfolio spans self-care, skin health and beauty, and essential health, with well-known brands such as Tylenol, Listerine, Neutrogena, Aveeno, Johnson’s, BAND-AID, Zyrtec, and Nicorette. The company’s products include over-the-counter medicines, oral care, skincare, baby care, wound care, allergy relief, and other routine wellness items used in homes, pharmacies, and healthcare settings. Kenvue serves a broad global customer base through retail, pharmacy, and digital channels, making it a significant participant in the consumer health market. Headquartered in Summit, New Jersey, Kenvue focuses on science-backed products designed to support daily health and personal care needs.

CEO Mr. Kirk L. Perry · 21,780 employees · United States · https://www.kenvue.com